A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world

Yin Wan1 Health Economics and Modeling, Outcomes Research, Pharmerit International, Bethesda, MD, USA

Shawn X Sun2 Health Economics and Outcomes Research, Forest Laboratories, LLC, an affiliate of Actavis, Inc., Jersey City, NJ, USA

Shelby Corman1 Health Economics and Modeling, Outcomes Research, Pharmerit International, Bethesda, MD, USA

Xingyue Huang2 Health Economics and Outcomes Research, Forest Laboratories, LLC, an affiliate of Actavis, Inc., Jersey City, NJ, USA

Xin Gao1 Health Economics and Modeling, Outcomes Research, Pharmerit International, Bethesda, MD, USACorrespondence[email protected]

Andrew F Shorr3 Pulmonary Critical Care, Washington Hospital Center and Georgetown University, Washington, DC, USA

Your download is now in progress and you may close this window